Lipoprotein(a) Levels Tied to Increased Risk of Recurrent Atherosclerotic CVD Events

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on May 21, 2025.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, May 21, 2025 -- Higher lipoprotein(a) levels are associated with continuously increasing risk of recurrent atherosclerotic cardiovascular disease (ASCVD) events, regardless of sex and race/ethnicity, according to a study published online May 7 in the European Heart Journal.

Noting that higher levels of lipoprotein(a) drive increasing risk of ASCVD in otherwise healthy individuals, Diane E. MacDougall, from the Family Heart Foundation in Fernandina Beach, Florida, and colleagues examined whether this is also true for recurrent ASCVD. Among U.S. medical claims between 2012 and 2022 for 340 million individuals, 273,770 had diagnosed ASCVD and lipoprotein(a) measures.

The researchers found that 15 percent of participants experienced recurrent ASCVD during a median follow-up of 5.4 years. There was an association for higher lipoprotein(a) levels with continuously increasing risk of recurrent ASCVD. For individual ASCVD components and in sex, race/ethnicity, baseline ASCVD, and diabetes subgroups, results were similar. The deleterious effect of lipoprotein(a) ≥180 nmol/L was possibly mitigated by high-impact low-density lipoprotein cholesterol (LDL)–lowering therapy, which was most pronounced for those on PCSK9 inhibitors (PCSK9i).

"Lipoprotein(a)-associated risk was similar regardless of baseline ASCVD and diabetes and may have been partially mitigated by the use of high-impact LDL cholesterol–lowering therapy, most pronounced in the case of PCSK9i use," the authors write.

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-05-22 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords